REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 499.77 Billion KRW | 3.11% |
| 2022 | 484.69 Billion KRW | 1.4% |
| 2021 | 477.97 Billion KRW | 50.49% |
| 2020 | 317.6 Billion KRW | 15.71% |
| 2019 | 274.48 Billion KRW | -9.46% |
| 2018 | 303.16 Billion KRW | 4.24% |
| 2017 | 290.84 Billion KRW | 38.8% |
| 2016 | 209.53 Billion KRW | -19.7% |
| 2015 | 260.92 Billion KRW | 36.44% |
| 2014 | 191.24 Billion KRW | 7.2% |
| 2013 | 178.39 Billion KRW | 13.69% |
| 2012 | 156.92 Billion KRW | 16.93% |
| 2011 | 134.2 Billion KRW | 17.94% |
| 2010 | 113.79 Billion KRW | 38.92% |
| 2009 | 81.91 Billion KRW | 25.64% |
| 2008 | 65.19 Billion KRW | 18.3% |
| 2007 | 55.11 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 494.92 Billion KRW | -0.97% |
| 2024 Q2 | 491.61 Billion KRW | -0.67% |
| 2023 Q1 | 480.47 Billion KRW | -0.87% |
| 2023 FY | 499.77 Billion KRW | 3.11% |
| 2023 Q3 | 499.24 Billion KRW | 0.15% |
| 2023 Q4 | 499.77 Billion KRW | 0.11% |
| 2023 Q2 | 498.49 Billion KRW | 3.75% |
| 2022 Q4 | 484.69 Billion KRW | 1.79% |
| 2022 Q3 | 476.15 Billion KRW | -0.33% |
| 2022 FY | 484.69 Billion KRW | 1.4% |
| 2022 Q1 | 476.27 Billion KRW | -0.36% |
| 2022 Q2 | 477.74 Billion KRW | 0.31% |
| 2021 Q3 | 472.89 Billion KRW | 18.26% |
| 2021 Q2 | 399.89 Billion KRW | 13.88% |
| 2021 FY | 477.97 Billion KRW | 50.49% |
| 2021 Q1 | 351.13 Billion KRW | 10.56% |
| 2021 Q4 | 477.97 Billion KRW | 1.07% |
| 2020 FY | 317.6 Billion KRW | 15.71% |
| 2020 Q1 | 279.89 Billion KRW | 1.97% |
| 2020 Q2 | 284.03 Billion KRW | 1.48% |
| 2020 Q3 | 294.58 Billion KRW | 3.71% |
| 2020 Q4 | 317.6 Billion KRW | 7.82% |
| 2019 Q2 | 285.15 Billion KRW | -7.69% |
| 2019 Q3 | 269.42 Billion KRW | -5.52% |
| 2019 FY | 274.48 Billion KRW | -9.46% |
| 2019 Q4 | 274.48 Billion KRW | 1.88% |
| 2019 Q1 | 308.91 Billion KRW | 1.9% |
| 2018 Q2 | 334.42 Billion KRW | 0.44% |
| 2018 Q1 | 332.95 Billion KRW | 14.48% |
| 2018 Q4 | 303.16 Billion KRW | -0.7% |
| 2018 FY | 303.16 Billion KRW | 4.24% |
| 2018 Q3 | 305.29 Billion KRW | -8.71% |
| 2017 Q3 | 279.37 Billion KRW | 0.0% |
| 2017 FY | 290.84 Billion KRW | 38.8% |
| 2017 Q4 | 290.84 Billion KRW | 4.1% |
| 2017 Q1 | - KRW | -100.0% |
| 2016 Q4 | 209.53 Billion KRW | 0.0% |
| 2016 Q2 | 238.59 Billion KRW | -3.57% |
| 2016 FY | 209.53 Billion KRW | -19.7% |
| 2016 Q1 | 247.42 Billion KRW | -5.17% |
| 2015 Q4 | 260.92 Billion KRW | 14.71% |
| 2015 FY | 260.92 Billion KRW | 36.44% |
| 2015 Q3 | 227.46 Billion KRW | -11.37% |
| 2015 Q2 | 256.65 Billion KRW | 26.62% |
| 2015 Q1 | 202.69 Billion KRW | 5.99% |
| 2014 Q4 | 191.24 Billion KRW | -1.27% |
| 2014 Q3 | 193.69 Billion KRW | 3.12% |
| 2014 Q1 | 185.16 Billion KRW | 3.79% |
| 2014 Q2 | 187.83 Billion KRW | 1.44% |
| 2014 FY | 191.24 Billion KRW | 7.2% |
| 2013 Q1 | 173.88 Billion KRW | 10.81% |
| 2013 Q3 | 174.9 Billion KRW | 0.35% |
| 2013 Q4 | 178.39 Billion KRW | 2.0% |
| 2013 Q2 | 174.3 Billion KRW | 0.24% |
| 2013 FY | 178.39 Billion KRW | 13.69% |
| 2012 Q1 | 139.34 Billion KRW | 3.83% |
| 2012 Q3 | 148.41 Billion KRW | 5.59% |
| 2012 Q4 | 156.92 Billion KRW | 5.74% |
| 2012 FY | 156.92 Billion KRW | 16.93% |
| 2012 Q2 | 140.55 Billion KRW | 0.87% |
| 2011 Q2 | 131.41 Billion KRW | -1.18% |
| 2011 Q1 | 132.98 Billion KRW | 16.86% |
| 2011 Q3 | 131.38 Billion KRW | -0.03% |
| 2011 Q4 | 134.2 Billion KRW | 2.15% |
| 2011 FY | 134.2 Billion KRW | 17.94% |
| 2010 Q3 | 106.39 Billion KRW | 3.2% |
| 2010 FY | 113.79 Billion KRW | 38.92% |
| 2010 Q4 | 113.79 Billion KRW | 6.95% |
| 2010 Q2 | 103.09 Billion KRW | 0.0% |
| 2009 FY | 81.91 Billion KRW | 25.64% |
| 2008 FY | 65.19 Billion KRW | 18.3% |
| 2007 FY | 55.11 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -152.14% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 74.464% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 43.013% |
| HANDOK Inc. | 790.33 Billion KRW | 36.764% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -192.917% |
| Yuhan Corporation | 2814.07 Billion KRW | 82.24% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 62.001% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -434.639% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 74.397% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -108.46% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -6.584% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -334.688% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -111.278% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -43.454% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -152.14% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -19.224% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 15.206% |
| JW Holdings Corporation | 1176.26 Billion KRW | 57.512% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 18.239% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 64.364% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 22.52% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -42.759% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -224.443% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -34.827% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -2.555% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -152.14% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 53.641% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 71.769% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 22.52% |
| Yuhan Corporation | 2814.07 Billion KRW | 82.24% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 43.207% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -120.553% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 49.707% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 22.52% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -19.022% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -6.594% |
| CKD Bio Corp. | 293.78 Billion KRW | -70.116% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 1.619% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 11.54% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -24.562% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -42.759% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 65.675% |
| Boryung Corporation | 922.36 Billion KRW | 45.816% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -12.953% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -6.584% |
| JW Lifescience Corporation | 255.83 Billion KRW | -95.35% |